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Abstract
Epilepsy and/or seizure activity are frequently occurring phenomena and a
significant co-morbid condition for persons with severe to profound intellectual
disability (Burke, McKee, Pathak, Donahue, Parasuraman & Baltenhorst, 1999).
The majority of seizure activity leads to deficits across a number of social,
physical, occupational, and personal variables, and if left untreated, may lead to
death in these individuals. The treatment of this condition frequently utilizes antiepileptic medication, but these medications are often associated with a variety of
side effects such as dental complications and disturbed gait. Previous researchers
have suggested that these side effects may be manifested in forms of maladaptive
behaviors such as aggression and destructiveness (Matson, Mayville, Bamburg &
Eckholdt, 2001), but studies have not yet been conducted to determine if side
effects of antiepileptics may manifest as feeding problems in this population.
Given that complications with feeding may incorporate some of the variables
mentioned above (i.e., dental complications), a relationship between the two is
likely. The purpose of this study was to evaluate feeding problems associated
with the use of three different types of antiepileptic medications on individuals
with severe to profound mental retardation as compared to their matched controls.
Individuals across three groups (clients on carbamazepine, n = 20; clients on
valproate, n = 18; and clients on phenytoin, n = 22) were compared to three
separate control groups matched on age, gender, race, and level of MR. They
were compared across items related to feeding problems on the Screening Tool of
fEeding Problems (STEP). Implications of these data are discussed.
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Introduction
Historically, individuals with mental retardation (MR) have received little in the
way of money and organized efforts toward assessment and treatment for their deficits. It
has only been since the 1850’s that the first public and private institutions for persons
with mental retardation were established in the United States (Hodapp & Dykens, 1996).
Since then, greater amounts of attention have been directed toward this population.
Specifically, assessment tools made especially for these individuals have been
constructed and a variety of treatment interventions have been applied. While there
continues to be a considerable debate over a multitude of issues concerning assessment
and treatment, substantial progress has been made and will most likely continue for years
to come.
In addition to possessing a variety of deficits in intellectual and adaptive areas,
persons with MR must often cope with physical abnormalities as well. The frequency
and severity of these may vary with the degree of the individual’s intellectual
impairment. Epilepsy is among the most common of these abnormalities, and may
present additional difficulties in a number of areas of functioning. The condition of
epilepsy in people with mental retardation has recently been receiving more attention
from researchers, as well as providers and administrators. This reflects advances that
have been made in the treatment of epilepsy in general and the need to extend these
advances to people with epilepsy and mental retardation (Coulter, 1993). Unfortunately,
medication side effects of antiepileptic medications, the primary treatment approach for
epilepsy in all populations, are abundant (Mayville & Matson, 2000). Side effects of
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antiepileptic medications often include variables such as sedation or adverse cognitive
effects that may further diminish the quality of life for those with MR. Behavioral
changes due to medication are also concerns (Rutecki & Gidal, 2002) addressed in many
clinical spectrums. Although studies show that behavioral manifestations of side effects
due to antiepileptic medications do exist, research has not looked at the relationship
between those on antiepileptic medications and feeding problems. The present study
represents the first step toward establishing a relationship between these two areas of
research. This approach would help enable future clinicians to make arguments for or
against the use of certain antiepileptic drugs when weighing the benefits of various
interventions for this underserved population.
Mental Retardation
As stated earlier, the major area of clinical practice and research for individuals
with MR has grown since the 1850’s. The reader should not be surprised, then, that the
treatment history before then was largely one of neglect. To begin with, the idea of
mental retardation was in and of itself a difficult concept to understand and accept. In
ancient Greece and Rome, infanticide was a common practice when children were
suspected to be developmentally delayed. For example, children were often thrown off
the edge of cliffs when found to be “defective” (Biasini, Grupe, Huffman, & Bray, in
press). In 1690, John Locke was the first to distinguish between mental retardation and
mental illness; “Herein seems to lie the difference between idiots and madmen, that
madmen put wrong ideas together and reason from them, but idiots make very few or no
propositions and reason scarce at all” (Doll, 1962).
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The first step towards the evolution in the care and treatment of the mentally
retarded was initiated by Jean-Marc-Gaspard Itard and Edouard Seguin in the early to
mid-nineteenth century. Itard developed a broad educational program for a young child
who was deaf and mute. Itard’s educational approach became widely accepted and
passed down to other physicians, namely Edouard Seguin, who then developed a
comprehensive approach toward the education of the mentally retarded. These broad
educational approaches were modified and are still in use today (Biasini, et al., in press).
Over the next 50 years, a newly developed test of intelligence by Binet was
translated into English and the Vineland Social Maturity Scale was developed. This scale
was used to assess the adaptive skills of individuals suspected of having mental
retardation. With the emergence of these assessment techniques, clinicians now believed
it was possible to determine who was mentally retarded and to provide them with
appropriate training in residential training schools (Biasini, et al., in press).
When the deinstitutionalization movement began in the later half of the twentieth
century and mentally retarded individuals began living in the community, those
prominent in the behavior modification movement began demonstrating that aberrant
behavior among those with MR could be treated (Matson & Sevin, 1994). Treatment
services began becoming available to mentally retarded individuals and their families,
and schools began placing emphasis on special programs for the developmentally
delayed. This finding was significant because it implied that simply being labeled “MR”
no longer suggested that nothing could be done to improve that person’s quality of life.
The definition of mental retardation has varied over time; early classifications
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were based on social competence, but more objective and intellectual criteria evolved
following the development of standardized intelligence tests in the early 1900’s (Mathias
& Nettlebeck, 1992). Substandard intellectual functioning, independent of adaptive
functioning, was considered when evaluating for mental retardation before the 1960’s
(Scheerenberger, 1987). However, in 1961, the American Association on Mental
Deficiency (AAMD) included in its definition of mental retardation the component of
“associated impairment in adaptive behavior” (Heber, 1961). This new addition,
although controversial, has been adopted into today’s definition of mental retardation.
The current definition as stated in the Diagnostic and Statistical Manual, Fourth Edition
(DSM-IV, American Psychiatric Association, 1994) is a combination of older and newer
definitions by AAMD of mental retardation, and includes three criterion: (1)
significantly subaverage intellectual functioning (IQ of 70 or below on standardized
intelligence test); (2) concurrent deficits or impairments in present adaptive functioning;
and (3) onset before the age of 18 years. Although the classification of substandard
cognitive functioning is objective and measurable (commonly defined as two standard
deviations below the mean on standardized intelligence tests), critics argue that the
concept of adaptive behavior is much more difficult to define and measure (Zigler, Balla,
& Hodapp, 1984). Despite this debate, the classification of mental retardation currently
includes the concept of adaptive behavior, and this inclusion helps to provide valuable
information that may prove useful in placement decision making and treatment planning.
Seizures and Epilepsy
As mentioned earlier, epilepsy in people with mental retardation has begun
receiving more attention from researchers as well as providers and administrators. Much
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of this is due to the advances in technology and treatment that have enabled clinicians to
provide better interventions for their clients. This section will explain the definition of
seizures and epilepsy, the prevalence of epilepsy, the etiology of the disorder, the
classifications of seizure activity, and finally the treatment common in the field.
Definition
A seizure is commonly viewed as a discrete event characterized by a sudden,
excessive, and disorderly (abnormal) discharge of neurons in the brain that is
accompanied by an abrupt alteration in motor and/or sensory function and/or
consciousness (Aicardi, 1986). The neuronal discharge may not be detectable by routine
scalp recordings of the electroencephalogram (EEG) in some seizures that do not affect
consciousness (partial simple seizures), but detectable alterations of the EEG is usually
present in seizures that do affect consciousness (partial complex and generalized
seizures) (Coulter, 1993). The evaluation of an individual with mental retardation who is
suspected to have seizures or epilepsy begins with a determination of whether the
behavioral events in question were really seizures (Coulter, 1993). Other causes for these
seizure-like behaviors include psychiatric disorders, muscle spasms (particularly in
people with cerebral palsy), paroxysmal movement disorders (such as tics,
choreoathetosis, or dystonia), vasovagal or cardiac syncope, sleep disorders (such as
narcolepsy or cataplexy), and migraine (Donat & Wright, 1990). Given these other
plausible explanations of seizure like activity, a diagnosis of a seizure disorder includes
behavioral observations and ruling out these other possible causes.
The definition of epilepsy is slightly more complex as various texts will explain it
in different ways. Epilepsy is commonly viewed today as a disorder characterized by
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multiple seizures (Trimble, Ring, & Schmitz, 2000). Seizure frequency specifications for
epilepsy diagnosis have included at least two within a two-year period. However, as
pointed out by Hopkins and Appleton (1996), in practice, a diagnosis of epilepsy is
frequently given if more than one seizure of any type is reported. Hopkins and Appleton
(1996) also stated that the definition of a seizure should also involve awareness of the
seizure to the person experiencing it and/or to an observer, given that abnormal neuronal
activity may in and of itself not indicate what is commonly defined as a seizure. In
addition, some argue that a continuing tendency for the individual to have seizures should
be acknowledged in a diagnosis of epilepsy, as more than one seizure induced by
traumatic events would not be representative of what is known as epilepsy (Hopkins &
Appleton, 1996). The debate continues on what exact frequency and duration of seizure
activity would be adequate to meet criteria for epilepsy, but most would agree that two or
more within a two year span is adequate.
Prevalence
Defined in this way, epilepsy affects approximately 1% of the general population.
However, it is well established that epilepsy is more prevalent in persons with mental
retardation than in the general population, with prevalence increasing as intellectual
functioning decreases (Bird, 1997). Altogether however, prevalence studies indicate that
between 5% to 50% of persons with mild to moderate impairment have epilepsy, and
between 26% to 67% of persons with severe to profound impairment have this condition
(Blomquist, Gustavson, & Holmgren, 1981; Coulter, 1993; Rutter, Tizard, Yule, Graham,
& Whitmore, 1976; Deb, 1997; Hollingsworth, 1978; McGrother, Hauck, Bhaumik,
Thorp & Taub, 1996).
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When considering the prevalence rates of epilepsy among those with mental
retardation, it is important to understand that the presence of comorbid physical and
neurological impairment, particularly cerebral palsy, influence the prevalence estimates
greatly. Eriksson, Erila, Kivimaki, and Koivikko (1998) found that cerebral palsy was
the single most important risk factor for severe epilepsy. Additionally, as observed by
Eriksson and colleagues (1998), persons with mental retardation and cerebral palsy who
have epilepsy tend to display a common set of characteristics, including a high initial
seizure frequency, early onset of seizures and multiple types, an increase in drug
resistance, lower long term remission rates, and a higher seizure recurrence rate following
anticonvulsant medication discontinuance. High prevalence rates of epilepsy may also be
due to other factors such as age, diagnosis of Down’s syndrome, Alzheimer’s, Rett
syndrome, Angelman syndrome, Lesch-Nyan syndrome and Lowe syndrome (Deb,
2000).
Etiology
The etiology behind epilepsy has been explained by theories ranging from the
supernatural to the biological. Most explanations rely on medical discrepancies in the
central nervous system or other areas of the body. A multitude of potential causes for
seizures exist, but the etiology is unknown in approximately 50% of cases (Rothner,
1983). In infants, genetic metabolic defects, anoxia, perinatal injury, and cogenital brain
defects are among the most common (Lennox, 1960; Volpe, 1981), while in children,
brain infections, trauma, vascular disease, endocrine disorders, and exposure to toxins
have been cited as more common causes (Lennox, 1960; Rothner, 1983). Head trauma is
a common cause of seizures in young adults (Hopkins & Appleton,1996; Rothner, 1983),
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and tumors are suspected as the cause underlying first seizures in persons over the age of
20 (Rothner, 1983). In patients over the age of 50, cerebrovascular disease (i.e., stroke)
is the most common cause of seizures (Rothner, 1983). Where no abnormality of the
brain or nervous system is found, a genetic predisposition for epilepsy is often present
(Rothner, 1983). To summarize, Cole (2002) broke down the possible causes of epilepsy
in the MR population into four distinct areas: Perinatal injury, remote central nervous
system infection, trauma, and developmental and genetic brain disorders.
Perinatal Injury – While the incidence of perinatal injury has decreased because of
improvements in obstetric care and technique, difficulties during delivery continue to be
a major risk factor for later development of sometimes disabling seizures (Cole, 2002).
Neurological injury during delivery may be related to prematurity, birth trauma (i.e.
forceps delivery), or perinatal hypoxia. Specifically, injury to the cortex and disruption
of normal neuronal migration are both likely to contribute to the later evolution of
seizures (Cole, 2002).
Remote Central Nervous System Infection – A history of remote central nervous
system infections is commonly found in institutionalized patients with epilepsy and
central nervous system dysfunction. Neonatal or childhood meningitis, for example, may
cause extensive gray matter injury with associated neurological deficits and chronic
seizures (Cole, 2002).
Trauma – Significant traumatic brain injury may result in severe seizure disorders
and neurocognitive dysfunction. Hemorrhage and depressed skull fracture are important
risk factors for posttraumatic seizures, whereas diffuse axonal injury may contribute to
cognitive and behavioral disturbance (Cole, 2002).
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Developmental and Genetic Brain Disorders – Structural disturbances of brain
development can occur throughout the period of brain formation and maturation. Recent
advances in neuroimaging, especially the development of magnetic resonance imaging
(MRI), have allowed the identification of a wide variety of developmental brain
abnormalities, and advances in genetics are leading to identification of an increasing
number of specific genetic abnormalities responsible for developmental disturbances
(Cole, 2002). In accordance with all of these theories, it is safe to say that the etiology of
epilepsy in individuals with MR is related to the cause of the retardation itself (Mayville
& Matson, 2000).
Classification of Seizure Activity
The International Classification of Epileptic Seizures (ICES) is widely recognized
as the primary system for classification of seizure activity. There are many different
subtypes of seizures, but most all of the common seizures in the MR population can be
classified under two primary divisions (Coulter, 1993). The two divisions under ICES
classification rules are generalized seizures (those that are generalized from onset) and
partial seizures (those that are partial or focal and their onset may or may not lead to
generalization).
Generalized Seizures - Generalized seizures are of two types – convulsive and
nonconvulsive. The common convulsive type is the tonic-clonic (grand mal) seizure. In
this particular type of generalized seizure, the patient may sense its approach by
experiencing symptoms such as the following: apathy, depression, irritability, and
occasionally ecstasy. In more than half the cases, some type of movement occurs before
consciousness is lost (Holmes, 1997). In others, there is palpitation, a sinking, rising, or
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gripping feeling, or some other supernatural sensation in another part of the body. Much
less often the seizure may strike without warning, in which the individual will suddenly
lose consciousness and fall to the ground. Tonic-clonic seizures are the most identifiable
and easily diagnosed of the generalized seizures, as they typically involve a loss of
consciousness with a simultaneous onset of generalized stiffening of the flexor or
extensor muscles (tonic phase), followed by generalized jerking of the muscles (clonic
phase) (Holmes, 1997).
The classic nonconvulsive generalized seizure is known as the absence (petite
mal) seizure. This type may be more difficult to recognize or diagnose. Absence
seizures are characterized by a sudden onset of impaired consciousness and an
accompanying blank facial appearance. Clonic activity (e.g., rapid eye blinking, jerking
of the arms), automatisms (simple behaviors which cannot be recalled, including rubbing
the face or hands, licking lips, or chewing), and automatic phenomenon (e.g., pupil
dilation, flushing, sweating) may also be present in complex absence seizures (Holmes,
1997). Often times, these seizures may be so brief that the patients themselves are not
aware of them. To some observers, it may even seem as if the individual that is
experiences this particular type of seizure is simply daydreaming.
Minor motor seizures such as myoclonic, tonic, or atonic seizures may be also
characterized under the heading of absence seizures. Myoclonic seizures are more brief,
shock-like contractions that may involve the entire body, but more commonly are
confined to one muscle or group of muscles. Frequently called “myoclonic jerks”, these
seizures may accompany an absence seizure or precede a generalized tonic-clonic
episode (Holmes, 1997). Tonic seizures are characterized by a brief period of sudden

10

increased tone in the extensor muscles which often result in a patient falling to the ground
if he or she is standing (Holmes, 1997). Finally, an atonic seizure (also known as “drop
attacks”) involve a sudden loss of muscle tone which may lead to falling, and are often
accompanied by myoclonic jerks before, during, and after seizure activity (Holmes,
1997).
Partial Seizures – Partial seizures differ from generalized seizures largely in their
location of origin. In generalized seizures, the location of origin is largely unknown, and
there is no reason to think that it resides in the cerebral cortex. On the contrary, partial
seizures are clearly the product of a demonstrable lesion in some part of the cerebral
cortex (Holmes, 1997).
Partial seizures can be divided into two main categories: Simple partial and
complex partial, depending on whether consciousness is retained or disturbed. Simple
partial seizures most often arise from foci in the sensorimotor cortex and are those in
which there is no disturbance in consciousness; subtypes include: with motor signs (i.e.,
focal motor seizure with spreading movement), with somatosensory or special sensory
symptoms (i.e., visual, auditory, olfactory), with autonomic symptoms or signs (i.e.,
sweating, flushing, papillary dilation), and with psychic symptoms (i.e., dysphasia,
cognitive, affective, illusions) (Drefuss, 1981).
Complex partial seizures most often have their focus in the temporal lobe on one
side of the other and are those in which consciousness is disturbed to some degree;
subtypes include the following: simple partial onset followed by impairment of
consciousness (with either simple partial features or automatisms), and those with
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impairment of consciousness at onset (with either impaired consciousness only or with
automatisms).
Treatment for Epilepsy
The treatment of epilepsy can be divided into three main categories: surgical
measures, behavioral treatment, and the use of antiepileptic medications. Because the
focus of this paper is primarily on antiepileptic medications, the other two categories will
not be discussed as thoroughly.
Surgical Measures – Patients with developmental disabilities, including
retardation and global developmental delay, are not ideal candidates for epilepsy surgery
(Olson, 2002). This is primarily due to the fact that most individuals with MR have an
increased likelihood of diffuse brain dysfunction, consequently meaning that there is an
increased chance that a focal cortical resection will not confer a major improvement in
their seizure frequency and severity (Olson, 2002). However, by applying the basic
principles of epilepsy surgery selection to this population, patients with a reasonable
likelihood of good seizure control can be identified.
Another form of surgery that has been developed recently is a vagus role
stimulator. Vagus nerve stimulation (VNS) was initially introduced in humans in 1988,
commercially introduced in Europe in 1994, and commercially introduced in the United
States in 1997 (Schachter & Saper, 1998). VNS is implemented using the following
products: a battery-powered implantable pulse generator, a bipolar platinum stimulation
lead, a programming wand and software for an IBM compatible laptop computer, an
intraoperative tunneling tool, and hand held magnets. The generator is subcutaneously
implanted in the patient’s left chest and is programmed externally with the laptop
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computer, using the programming wand. The stimulation lead wire is inserted through an
incision in the neck, attached to the vagus nerve, and tunneled subcutaneously down the
neck and to the generator. The device is programmed to deliver intermittent electrical
stimulation to the left vagus nerve, and consequently reduce seizure activity. Passing a
magnet over the device activates an internal switch, which can be used to suspend VNS
or to provide an extra dose of stimulation (Wilfong, 2002). VNS therapy meets many of
the challenges presented by the MR population with difficult-to-control seizures, but this
procedure is still relatively new.
In addition to this, it is important to remember that other options must always be
considered first before the option of surgery. For example, in cases where a reasonable
trial of antiepileptic drugs has failed to provide adequate seizure control, little is lost by
investigating the possibility of surgical treatment of medically refractory seizures (Olson,
2002).
Behavioral Treatment – Although medical intervention is the most common form
of treatment for individuals with epilepsy, the notion that seizures may result from an
interaction of biological and environmental factors has lead to new behavioral treatments.
Current efforts to proliferate a behavioral medicine approach to epilepsy are currently
focused primarily outside of the realm of MR, but a groundwork within the area of MR
has been established upon with further efforts can be built (Mayville & Matson, 2000).
A number of researchers have recently explored the use of contingency
management in treating children and mentally retarded adults with epilepsy. Gardner
(1967) demonstrated that treatment involving altering reinforcement contingencies helped
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eliminate psychogenic seizures in a 10 year old girl. Gardner also suggested that a
functional relationship between seizure activity and parental attention was evident.
Another study was used to demonstrate how the interruption of antecedent
behavioral chains could inhibit seizure activity of varying types (Zlutnick, Mayville, &
Moffat, 1975). Five children with varying degrees of MR and several other related
problems (i.e., autism) participated in a study in which their seizure activity was
significantly reduced utilizing techniques such as interruption (firmly grasping the
individual and stating “No!”) and differential reinforcement (verbal praise, receipt of
candy following successful redirection) just prior to the seizure activity.
Although a handful of studies have been done supporting the use of behavioral
interventions for people with MR and epilepsy, there still lies a need for more
scientifically rigorous studies in order to draw firm conclusions about the efficacy of
these treatments.
Antiepileptic Medications – Drug treatment is by far the most widely effective
mode of treatment for epilepsy (Mycek, Harvey, Champe, 1997). However, epilepsy in
the MR population is often particularly difficult to treat for several reasons: the presence
of several different seizure types, the presence of significant brain abnormality or
dysfunction, initial resistance to antiepileptic medication, and early onset of epilepsy
(Alvarez, 1998). Consequently, practices of antiepileptic medication use in this
population often incorporate methods normally avoided with the population at large (i.e.,
polypharmacy). One study confirmed this by surveying antiepileptic medication use in a
sample of 143 adults with MR (Deb and Joyce, 1999). The authors found that 42% of
this sample were receiving polypharmacy and of this percentage, 28%, 12.6%, and 1.4%
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were taking two, three, and four antiepileptic medications respectively. Given the
toxicity of some antiepileptic medications, monotherapy is usually preferred over
polypharmacy.
Antiepileptic medication, when used appropriately and in therapeutic dosages, can
be efficacious in preventing seizure activity. However, when choosing which medication
to administer, it is important to obtain an accurate seizure diagnosis first and foremost.
This is particularly important because different antiepileptics may be better for different
types of seizures. For example, studies have demonstrated that carbamazepine is the drug
of choice for the treatment of partial epilepsy (Pellock, 2002).
Although there are a number of antiepileptic medications to choose from, the
study at hand compares only three of the most common ones. Consequently, those three
particular medications will be discussed in great detail, while the other medications will
be briefly summarized.
Carbamazepine (Tegretol) - Closely related to imipramine and other
antidepressants, carbamazepine is a tricyclic compound effective in the treatment of
bipolar depression. It has also proven to be efficacious in treating individuals with
epilepsy as well (Pellock, 2002). For many neurologists, carbamazepine is the first drug
of choice for the treatment of partial epilepsy, particularly for its lack of sedation and low
incidences of cosmetic, cognitive, and behavioral side effects. It is not shown to be
effective for absence, atonic, and myoclonic seizures and may actually worsen these
seizure types (Perruca, Gram, Avanzini, & Dulac, 1998). Adverse behavioral side-effects
have been documented in this population, but reports are few and have been limited to
exacerbation of pre-existing behavior problem in patients taking carbamazepine for
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behavioral or psychiatric reasons (Friedman, Kastner, Plummer, Ruiz, & Henning, 1992).
While neurotoxicity can occur, it tends to be dose related and reversed with a decrease in
dosage (Waisburg & Alvarez, 1998). In addition to the side affects mentioned above,
researchers suggest that carbamazepine may irritate the stomach, and nausea and
vomiting may occur (Mycek, Harvey, & Champe, 1997). Obviously, problems such as
these may be manifested as feeding or mealtime behavior problems.
Valproate (Depakote/Depakene) – Valproate is an especially attractive choice for
the treatment of epilepsy in the MR population because of its acceptable tolerability
profile and ability to reduce multiple seizure types (Friis, 1998). Valproate is very
effective against absence seizures, however, it is also effective with tonic clonic attacks
(Pellock, 2002). Some evidence also exists that valproate is effective in partial seizures
(Pellock, 2002). Few adverse effects are reported in patients that use valproate, but
hepatotoxicity associated with valproate treatment, though rare, is potentially fatal and
can be more likely to occur in persons with MR (Friis, 1998). Additionally, coagulation
problems, hemorrhaging, or easy bruising may occur, and these factors may exclude
patient with self-injurious behavior from this treatment (Alvarez, et al., 1998). Finally,
valproate has been found to possibly cause nausea and vomiting in individuals with
epilepsy (Mycek, Harvey, & Champe, 1997). Problems such as these are often
considered feeding or mealtime behavior problems in this population.
Phenytoin (Dilantin) – Phenytoin is the oldest, nonsedative antiepileptic drug,
introduced in 1938 following systematic research in the laboratory (Pellock, 2002).
Phenytoin is also known as one of the most effective drugs against partial seizures and
generalized tonic clonic seizures. However, the adverse side effects of phenytoin are
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numerous and wide-ranging, and present special problems to individuals with mental and
physical complications (Mayville & Matson, 2000). Most troubling are the adverse
neurological effects, which are often irreversible (Iivanainen, 1998). Deterioration of
intellectual and cognitive functioning, drowsiness, truncal or limb ataxia, progressive
motor coordination complications, and loss of locomotion have all been documented
(Iivanainen, 1998). Few studies exist evaluating the side effects of this medication in this
population; however, it does appear that certain mentally retarded individuals may be
more adversely affected by specific phenytoin side effects than individuals with normal
intelligence (Mayville & Matson, 2000). Iiavanainen, Viukari, and Helle (1977) found a
28% rate of cerebellular atrophy secondary to phenytoin toxicity in a sample of 131
patients with MR, with 23.5% of the sample displaying a persistent loss of locomotion.
Finally, as related to this study, researchers suggest that phenytoin may cause
gastrointestinal problems (nasea, vomiting) and possibly gingival hyperplasia (gums to
grow over the teeth) (Mycek, Harvey, & Champe, 1997). Obviously, side effects such as
these may be manifested as feeding or mealtime problems.
Other Antiepileptic Medications - Although carbamazepine, valproate, and
phenytoin are used frequently when treating epilepsy in the MR population, there are
some other anti-epileptics that are used with this population as well.
Phenobarbital, the most familiar of the barbiturates, has been used as an
antiepileptic in persons with MR since its introduction in 1912 (Alvarez, 1998). This
particular antiepileptic has been shown to be somewhat efficacious for simple partial
seizures, but not very effective for complex partial seizures (Mycek, Harvey, & Champe,
1997). In addition, phenobarbital use in persons with mental retardation has been
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associated with depression (Trimble & Corbett, 1990), lowered frustration tolerance
(Gay, 1984), hyperactivity (Burd, Kerbeshian, & Fisher, 1987), conduct disorder
(Trimble & Corbett, 1990), and exacerbation of pre-existing hyperactive and aggressive
behavior (Ingram, 1986).
Several of the benzodiazepines show antiepileptic activity. Clonazepam and
clorazepate are used for chronic treatment of epilepsy. While clonazepam is effective in
absence and myoclonic seizures, clorazepate is efficacious in the treatment of partial
seizures when used with other drugs (Mycek, Harvey, & Champe, 1997). Of all the
antiepileptics, benzodiazepines are often considered the safest and most free from severe
side effects, although they may have sedative properties (Mycek, Harvey, & Champe,
1997). Despite this, their efficacy isn’t well proven, thus they are often only used in
adjunctive roles and emergency situations.
There are a number of newer antiepileptic medications that have surfaced within
the last 20 years. These newer medications have been reported to be efficacious and are
reported to have fewer adverse effects (i.e., gabapentin, lamotrigine, tigabine,
zonisamide, toprimate, vigabatrin, oxcarbazepine, etc.) (Mayville & Matson, 2000). The
research demonstrating the efficacy of these newer drugs is limited, but multiple drug
trials are being done in order to draw firm conclusions. Perhaps the biggest drawback of
using the newer agents is a different spectrum of side effects, which includes anorexia
and behavioral changes. Although these side effects do exist with these newer drugs, the
possibility of producing a significant reduction in seizures makes the effort worthwhile
(Rutecki & Gidal, 2002). Additionally, the relationship of these drugs to problems such
as feeding and mealtime behaviors is of considerable importance.
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Feeding and Mealtime Behaviors
Individuals diagnosed with mental retardation have a higher prevalence of
comorbid disorders and behavior problems than the general population (BorthwickDuffy, 1994; Matson & Barret, 1993). One area that continues to be a growing concern
among clinicians with MR clients are feeding and mealtime problems. Although feeding
problems are a serious health concern for clients with MR, most of the research on
feeding disorders has focused on children, primarily without MR. The literature that
examines feeding problems among adults with MR is small in quantity, and consists
primarily of case studies that use functional based assessments that are descriptive in
nature. This section will explain the background, prevalence, identification, evaluation,
and treatment of feeding and mealtime problems.
Background of Feeding and Mealtime Problems
The area of feeding problems in individuals with MR was initially described in
1983. Linscheid (1983) described ten mealtime problems including tantrums, bizarre
food habits, multiple food dislikes, food-texture selectivity, delay or difficulty in
chewing, sucking, or swallowing, delay in self feeding, pica, excessive overeating, too
little food eaten, and rumination. In 1989, Sisson and Van Hasselt suggested that feeding
problems could be divided into four categories: 1) lack of independent skills, 2)
disruptive behavior, 3) eating too much or too little, and 4) selectivity by type or texture.
Currently, a wide variety of different disorders, diagnoses, skill deficits, and excess
behaviors fall under the rubric of “feeding problems.” These include: (a) failure to thrive
(FTT), a term descriptive of children who have trouble gaining weight, often due to
serious pediatric ailments (Harnill, Drizd, Johnson, Reed, Roche, & Moore, 1979; Heffer
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& Kelly, 1994; Stickler, 1984); (b) feeding disorder of infancy or early childhood, a
formal diagnostic category for children who persistently fail to eat adequately and gain
weight; (c) rumination disorder, characterized by repeated regurgitation and re-chewing
of food; and (d) pica, which is the persistent eating of non-nutritional substances
(Girolami, P.A. & Scotti, J.R., 2001). Problems such as food refusal have often been
associated with infants and children (Johnston, 1993; Parry, 1994; Riordan, Iwata,
Finney, Wohl, & Stanley, 1984), but these problems are also prevalent among older
individuals with MR as well.
To date, the identification of feeding problems among adults with mental
retardation has not been systematically formalized. In state hospitals and developmental
centers, a nutritional management committee usually consisting of an occupational
therapist, a nutritionist, and a physician among others are in charge of identifying feeding
problems. In addition to this, staff and caregivers are encouraged to alert physicians
when problems occur during mealtimes. Without a formal system for identifying feeding
problems, however, prevalence estimates are difficult to ascertain. In the next section the
prevalence of feeding and mealtime problems in the MR population will be explored.
Prevalence of Feeding and Mealtime Problems
Due partly to the lack of a formal identification system for identifying feeding
problems, the prevalence estimates for the occurrence of feeding problems vary.
Researchers estimate that mealtime problems occur among one third of the children with
developmental disabilities (Gouge & Ekvall, 1975; Palmer, Thompson, & Linscheid,
1975), but Perske, Clifton, McClean, & Stein (1977) have found that the greater the level
of the retardation, the more prevalent the problem. For example, 80% of severely or
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profoundly retarded individuals are estimated to have mealtime problems (Perske, et al,
1977). Matson, Gardner, Coe, and Sovner, (1991) estimated the prevalence of eating
disturbance at 27.5% among a sample of 506 individuals with MR residing across two
state-run facilities. Matson, et al., (1991) also found that feeding problems appear to be
more prevalent among those with more profound levels of MR.
As prevalence estimates show that feeding problems are relatively more common
among the profoundly retarded individuals than the mild and moderate, it becomes
increasingly difficult to identify and assess these problems. When patients are nonverbal
and unable to describe their symptoms, it becomes the clinician’s job to identify the
problem through observable behaviors. For example, a client who is feeling nauseous
may refuse food or eat only a small portion. In order to determine the best course of
treatment, it is necessary for the clinician to be able to observe certain behaviors, identify
the association of the problem with its antecedents, and subsequently take the most
appropriate form of action that fits the client’s needs. For example, if a patient has been
on an antiepileptic for a significant amount of time and suddenly begins ruminating their
food (bringing food past his/her airway repeatedly) on a daily basis, it may be rumination
resulting from gastro-esophageal reflux disease (GERD). Essentially, the client may not
be ruminating for attention, self stimulation, or escape. Rather, it could be a side effect of
antiepileptic use. In this case the clinician may want to consider titrating the client’s
neuroleptics, or eliminating any anticholinergic medications. On the other hand, if the
individual refuses to eat certain foods (i.e. tomatoes) because it exacerbates their GERD,
then the clinician may consider a different intervention to suppress the reflux (i.e. acidsuppressing medication, or modifying the individual’s diet). Clearly, identifying feeding
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problems and their antecedents are a very important step toward finding the most
appropriate treatment for an individual, and this will be discussed next.
Identification of Feeding and Mealtime Problems
As mentioned previously, there is currently no formal identification process for
feeding problems, and feeding problems due to the use of antiepileptics or psychotropic
medications may be overlooked or treated inappropriately. However, some rating scales
have proven useful for identifying the presence of feeding problems in individuals with
mental retardation. Scales such as the Reiss Screen (Reiss 1988) and the Diagnostic
Assessment for the Severely Handicapped-II (DASH II) (Matson, et al., 1996) include
items that address problems related to weight gain or loss resulting from overeating or
insufficient eating. Recently, a new scale has been developed that focuses strictly on
common feeding problems in persons with MR. This tool is known as the Screening
Tool of fEeding Problems (STEP) and allows for the quick and efficient identification of
specific feeding and mealtime behavior problems exhibited by individuals with MR
(Matson & Kuhn, 2001).
The STEP is a measure developed specifically for the assessment of common
feeding problems among those with MR. There are 23 items on the STEP representing
five rationally derived categories/subscales of feeding problems. These include: (1)
aspiration risk, (2) selectivity, (3) skills, (4) food refusal related behavior problems, and
(5) nutrition related behavior problems. These questions are designed in a Likert-type
format, with three possible responses for both frequency and severity of the target
behavior in the last month: (0) = never occurs, (1) = occurs between 1 and 10 times,
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(2) = occurs more than 10 times, for frequency ratings; and (0) = causes no harm or
problems, (1) = causes minimal harm or problems, and (2) = causes serious injury or
problems, for severity ratings (Matson & Kuhn, 2001). The STEP possesses acceptable
test-retest (r = .72, p<.01) and cross rater reliability (r = .71, p<.01). In addition, items on
the STEP related to pica and rumination were significantly correlated with DSM-IV
diagnoses of rumination and pica (Matson & Kuhn, 2001). To date, the STEP represents
the only measure specific to feeding problems in the MR population.
Evaluation of Feeding Problems
Once a feeding problem(s) has been identified using observation methods as well
as the tools described above, an interdisciplinary team for evaluation and treatment is
essential. An evaluation such as this may incorporate input from a physician,
occupational therapist, dietician, and psychologist. With the combined effort of all of
these disciplines, the client stands a better chance of having every aspect of possible
treatment addressed. The following paragraphs explain how each discipline can
contribute toward a successful treatment plan for the individual.
A physician would be imperative for a medical assessment in which the following
is assessed: the client’s upper gastrointestinal anatomy to ensure that the individual can
protect his/her airway during swallowing (Babbitt, Coe, Cataldo, Kelly, Stackhouse &
Perman, 1994); the mucosal lining of the esophagus, stomach and duodenum which
provides information about whether medical conditions exist (i.e., esophagitis,
esophageal reflux) (Babbitt et al., 1994); the upper gastro-intestinal tract for evaluating
motility (Babbitt et al., 1994); and measuring intraesophageal pressure which provides
information about peristalsis and thus esophageal motility (Patti, Diener, Tamburini,
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Molena, & Way, 2001). The medical information gathered by physicians may help
identify feeding problems that occur due to medical conditions and the client can then be
treated specifically for each condition. In addition to this, an occupational therapist plays
an important role that contributes toward the wellbeing of the client.
An occupational therapist helps examine the individual’s coordination and
physical ability to perform various tasks necessary for feeding (O’Brien, Repp, Williams,
& Christophersen, 1991). The skills evaluated that are necessary for oral feeding include
oral pharyngeal reflexes and oral-motor skills that include sucking, swallowing, chewing,
and tongue control. Skills evaluated necessary for self-feeding include hand-eye
coordination, motor development, and gross reflective movements. All of these skills,
once evaluated by the occupational therapist, can identify feeding problems that may be
due to an individual’s physical inability to perform feeding tasks. In addition to the
expertise provided by the physician and occupational therapist is the dietician, whose
skills are essential for nutritional knowledge.
A dietician provides valuable information pertaining to feeding problems
(O’Brien, et al., 1991). For example, just as for normal growing children, eating all the
necessary nutrients is important to maintain health in an individual with mental
retardation. A dietician is able to evaluate a client’s diet and ensure that all the necessary
nutrients are consumed. In addition to this, a dietician can assess food allergies or
identify when a client may have an inability to digest certain foods. Finally, a dietician
can evaluate an individual’s weight and recommend a diet which provides the right
amount of calories to ensure the client’s health. Although there are many feeding
problems and mealtime behaviors that may be accounted for by the disciplines mentioned
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above, it is also important to have a psychologist who can identify environmental
variables that contribute to or exacerbate feeding problems.
A psychologist can identify feeding problems that exist due to behavioral issues.
For example, if a client does not enjoy mealtime, he/she may become physically
aggressive in the dining area. Consequently, he/she may be led out of the dining area and
put into a quiet room. Behaviorally, physical aggression during feeding times serves as
an escape function for this particular client. A psychologist may conduct an analogue
functional assessment to determine what exact function the client’s behavior is serving
(Iwata, et al., 1994). By manipulating the consequence following the feeding problem
behavior, the function can be identified and addressed.
Clearly, the use of an interdisciplinary team including a physician, occupational
therapist, dietician, and psychologist may help in identifying feeding problems and aide
in developing an appropriate treatment. Since the lack of research in this area does not
permit firm conclusions on many areas related to feeding problems, it is therefore
essential that more systematic research is done to ensure that health care professionals are
better equipped to deal with the dangers that may arise in the future.
Treatment of Feeding Disorders
Literature related to feeding disorders has focused primarily on the functional and
medical aspects of eating behavior. Little is known about treatment for specific feeding
problems. Studies have shown that treatment usually incorporates multiple components
including different reinforcement strategies (i.e., contingent attention or tangible
reinforcement), noncontingent reinforcement escape extinction, antecedent manipulation,
and negative reinforcement techniques (Cooper, et al., 1995). These procedures are
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frequently cited in the treatment of food refusal and food selectivity (Cooper et al., 1995).
In addition to these procedures, aversive techniques are sometimes used in the treatment
of life-threatening behaviors such as pica and rumination (Gravestock, 2000).
In regards to behavioral treatment for the development of appropriate mealtime
behavior (i.e., appropriate utensil use and chewing behavior), instructions, prompts,
modeling, manual guidance, behavioral rehearsal, and contingent attention have all been
successfully utilized (Sisson & Dixon, 1986). Behavioral techniques have also been
effective in reducing behaviors that interfere with feeding such as mealtime rapid eating
(Favell, McGimsey, & Jones, 1980), and mealtime sloppiness (Cipani, 1981).

26

Purpose
The purpose of the current study was to evaluate the relationship between feeding
problems and the use of specific types of antiepileptic medications. Previous research
shows that many antiepileptic medications used with this population have adverse side
effects, some of which exacerbate behavior problems (i.e., increase in SIB, aggression,
destructiveness) (Kerr, 2002). In addition to this, side effects of many of these
medications have properties that are related to stomach problems and dental
complications, and these specific side effects may manifest themselves as feeding and
mealtime behavior problems. Feeding and mealtime behavior problems are extremely
common among individuals with mental retardation (Matson & Kuhn, 2001), and
consequently has become a growing area of research among clinicians in the field.
Palmer, Thompson, and Linscheid (1975) estimated that 33% of persons with mental
retardation had severe feeding difficulties and problems. Furthermore, the consequences
of untreated feeding problems can be serious, if not fatal.
Given the extensive research on antiepileptics, researchers generally agree that
phenytoin is associated with the most frequent and most severe adverse side effects when
compared to other antiepileptics, although other antiepileptics have minor side effects as
well. Consequently, it was hypothesized that those individuals that were on phenytoin
were most likely to have significantly more feeding problems than their matched
controls, while those on carbamazepine and valproate are not expected to differ
significantly from their matched controls.
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Method
Participants
Information was obtained on 120 individuals residing at the Pinecrest
Developmental Center (PDC) in central Louisiana. PDC is a state-run facility that
consists of individual homes under 24 hour supervision. Approximately 650 individuals
are housed at PDC and the gender, race, and level of mental retardation vary throughout
the center. Approval from the Institutional Review Board (IRB) was obtained.
The present study was divided into three separate parts, each with one
experimental group and one control group. The experimental groups consisted of the
following: (1) a group of 20 clients who were only on carbamazepine, (2) a group of 18
clients who were only on valproate, and (3) a group of 22 clients who were only on
phenytoin. All participants were on these medications for at least five months. All the
experimental groups also maintained the following criteria: (1) no participant had an axis
I disorder, (2) no participant was on any psychotropic medication, and (3) each
participant had to receive a diagnosis of either tonic-clonic epilepsy or tonic-clonic and
partial epilepsy from a staff neurologist.
Each experimental group was matched to non-medicated controls. They were
matched case by case according to age (within 10 years), gender, race, and level of
mental retardation. Members of the control group were not on any medications, did not
have any instances of seizure activity, and did not have any Axis I diagnoses. Diagnoses
of mental retardation were made previously by licensed psychologists using DSM-IV
criteria.
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Dependent Variable
The Screening Tool for fEeding Problems (STEP) – The STEP is a 23 item informant
based questionnaire that was designed to screen for a variety of feeding problems. This
test consists of five rationally derived subscales (1) aspiration risk, (2) selectivity, (3)
feeding skills, (4) refusal related behavior problems, (5) nutrition related behavior
problems. Test-retest reliability (r = .72) and crossrater reliability (r =.71) were found to
be acceptable. In addition, the rumination and pica subscales demonstrated criterion
validity through a correlation with DSM-IV diagnoses for rumination and pica (Matson &
Kuhn, 2000).
Procedure
Data was gathered by interviewing the primary caregiver for each of the 120
selected clients on the STEP. Due to the participant’s inability to self report, caregivers
who were particularly familiar with the feeding habits of the participants were
interviewed. First the staff were questioned on the frequency of each item. If the staff
rated the frequency as either a “1” (occurring between 1 and 10 times in the last month)
or a “2” (more than 10 times in the last month), the interviewer questioned the staff on
item severity. The severity questions could also be rated on a scale from 0 to 2. A rating
of “0” (caused no harm/problems), “1” (caused minimal harm or problems) or “2”
(caused serious injury or problems) comprised the severity scale. Although the items on
severity provided important information for clinicians, only frequency items were
assessed for the purposes of this study. This was primarily due to the fact that the
frequency items appeared to be the most objective of the two. All STEP questionnaires
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were administered within a 3 week period by bachelor and masters level college
graduates.
Experimental Design
This design was divided into three separate studies because each experimental
group was matched to a separate control group. Therefore, comparisons could not be
made across experimental groups and separating those groups into different studies
appeared to be the most logical method of design. The first study looked at the
differences between participants on carbamazepine and their matched controls, the
second study looked at the differences between participants on valproate and their
matched controls, and the third study looked at the differences between participants on
phenytoin and their matched controls.
Since the analyses for each study consisted of 5 t-tests, a Bonferroni correctional
formula was utilized to minimize the inflation of alpha error. According to Stevens
(1996), setting the original alpha level to .10 is considered acceptable in situations where
the chances of making a Type II error is of greater consequence than of making a Type I
error. Because of the possible life threatening nature of feeding disorders, concerns of
overlooking any significant results may be of serious consequence (i.e., injury or even
death). Therefore, an alpha level of .10 was used. Given these considerations, a final
alpha level of .02 was used after the Bonferonni correctional procedure was applied.
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Results
For each study, an analysis was done to determine whether there were
significantly more participants on G-tubes in the experimental group versus their matched
controls. A G-tube is a device that allows nutrients to enter a client’s body through a tube
connected to their stomach. A participant that is on a G-tube is not able to engage in
many of the behaviors on the STEP (i.e., eat only certain foods, vomit) and this could
have consequently confounded the results. Only in the second study (the valproate
experiment) were there significantly more G-tube feeders in the experimental group than
in the control group. For this reason, the same analyses were run after removing the Gtubers from the experiment, and the same results were found.
Because of the large number of comparisons evident in the design, only five
subscales of the STEP were analyzed. The five were statistically derived subscales
chosen due to their relatively high inter-item consistency (see Matson & Kuhn, 2001),
and to their inclusion of items stated in the literature on adverse side effects of seizure
medications. The literature specifically stated that individuals on these particular seizure
medications have shown adverse side effects such as vomiting and food refusal (Mycek,
1997); consequently, it was ensured that the five chosen subscales included items related
to these particular side effects. Table 1 on the next page shows the five empirically
derived subscales, their content, and their inter-item consistency.
Study I
Clients in the carbamazepine group were matched successfully on age (within 10
years), gender, race, and level of MR with controls in a matched cohorts design (Hinkle,
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Table 1
Inter-item consistency
Factor
Food Refusal Items
selective by type of food
eats small amount
spits out food
pushes food away
selective by feeder
Stealing/Pica
steals food at mealtime
eats non-food items
steals food at other times
Feeding Skills
cannot feed independently
requires special equipment
requires special positioning
Eats Large Amount/Fast Eater
eats all available food
eats too quickly
insufficient chewing
Vomit/Rumination
problem behavior during meals
ruminates
vomits

Coefficient α
.70

.66

.56

.53

.42

Wiersma, & Jurs, 1998). Prior to the main analyses, a chi square analysis was used and
no significant difference was found in the use of the G-tube between participants on
carbamazepine and their matched controls, X2 (1)=.00, N = 40, NS. The main analyses
consisted of 5 independent sample t-tests that were conducted using each of the
empirically derived subscales as the dependent variables, and group (experimental and
control) as the independent variables. A Bonferonni correctional procedure was used to
minimize the inflation of alpha error, leaving a significance cutoff level of p<.02. Based
on these analyses, it was determined that the only feeding problem that was significantly
different between the participants on carbamazepine (M = 3.25) and their matched
controls (M = 2.00) was the feeding skills subscale, t(38) = 2.47, p<.02. Table 2
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illustrates a comparison between the two groups of the means and standard deviations for
each of the subscale scores. This table also includes the statistical results of each
analysis.
Table 2
Means, standard deviations, and statistical results for each empirically derived subscale
Subscale
Carbamazepine
Control
Analysis
Food Refusal Items
M 1.15
1.40
p = .66
SD 1.98
1.64
Stealing/Pica
M .00
.35
p = .12
SD .00
.99
Feeding Skills
M 3.25
2.00
p = .02*
SD 1.62
1.59
Eats large amount/fast eater
M .45
.50
p = .88
SD 1.05
1.05
Vomit/Rumination
M .20
.30
p = .57
.57
SD .52
*significance found with alpha set at .02
To elucidate which individual items were accounting for the majority of the
between-group variance, an item analysis was conducted. The three individual items that
compromised the empirically derived feeding skills subscale were: cannot feed
himself/herself independently, requires special equipment for feeding, and requires
special positioning during feeding. Three independent t-tests were utilized and no
significant differences between the participants on carbamazepine and their matched
controls were found on each individual item. A Bonferonni correctional procedure was
used to minimize the inflation of alpha error, leaving a significance cutoff level of p<.02.
However, it was apparent that the item regarding whether the participants needed special
equipment seemed to be nearing significantly greater proportions in the carbamazepine
group (M = 1.65) than the control group (M = 1.10), t(38) = 1.95, p=.06. Table 3
illustrates a comparison between the two groups of the means and standard deviations for
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each of the individual item scores. This table also includes the statistical results of each
analysis.
Table 3
Means, standard deviations, and statistical results for each individual item score
Item
Carbamazepine
Control
Analysis
Cannot feed independently
M 1.00
.500
p = .12
SD 1.03
.89
Requires special equipment

M 1.65
SD .75
Requires special positioning
M .60
SD .94
*significance found with alpha set at .02

1.10
1.02
.40
.82

p = .06
p = .48

Study II
Clients in the valproate group were matched successfully on age (within 10
years), gender, race, and level of MR with controls in a matched cohorts design (Hinkle,
Wiersma, & Jurs, 1998). Prior to the main analyses, a chi square analysis was used and a
significant difference was found in the use of the G-tube between the participants on
valproate and their matched controls, X2 (1,N=36) = 4.5, p<.05. Specifically, the group
on valproate had significantly more G-tube feeders than their matched controls. The
main analyses consisted of 5 independent sample t-tests that were conducted using each
of the empirically derived subscales as the dependent variables, and group (experimental
and control) as the independent variables. A Bonferonni correctional procedure was used
to minimize the inflation of alpha error, leaving a significance cutoff level of p<.02.
Based on these analyses, it was determined that there were no significant differences in
feeding problems between the participants on valproate and their matched controls.
However, those participants on valproate (M = 3.11) did appear to be approaching
significance regarding differences in feeding skills than their matched controls (M =
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1.78), t(34) = 2.28, p = .03. Because the groups were already shown to differ
significantly with respect to having more G-tube feeders in one group, the G-tube feeders
were removed from the pool and the t-tests were rerun. Results were the same.
Specifically, participants on valproate (M = 3.14) still had more feeding skill problems
than those in the control group (M = 1.78), t(30) = 2.09, p<.05., and these results were
approaching significance. Table 4 illustrates a comparison between the two groups of the
means and standard deviations for each of the subscale scores after G-tube feeders were
removed. Table 4 also includes the statistical results of each analysis.
Table 4
Means and standard deviations for each empirically derived subscale
Subscale
Valproate
Control
Food Refusal Items
M 1.07
1.56
SD 1.94
1.50
Stealing/Pica
M 7.14E-02
.17
SD .27
.51
Feeding Skills
M 3.14
1.77
1.80
SD 1.88
Eats large amount/fast eater
M 1.21
.33
SD 1.85
.69
Vomit/Rumination
M .50
.39
.70
SD .85
* significance found with alpha set at .02

Analysis
p = .43
p = .54
p = .05
p = .11
p = .69

Study III
Clients in the phenytoin group were matched successfully on age (within 10
years), gender, race, and level of MR with controls in a matched cohorts design (Hinkle,
Wiersma, & Jurs, 1998). Prior to the main analyses, a chi square analysis was used and
no significant difference was found in the use of the G-tube between the participants on
phenytoin and their matched controls, X2 (1)=.29, N = 44, NS. The main analyses
consisted of 5 independent sample t-tests that were conducted using each of the

35

empirically derived subscales as the dependent variables, and group (experimental and
control) as the independent variables. A Bonferonni correctional procedure was used to
minimize the inflation of alpha error, leaving a significance cutoff level of p<.02. Based
on these analyses, it was determined that there were no significant differences on feeding
problems between the participants on phenytoin and their matched controls. However,
those participants on phenytoin (M = 2.82) did appear to be approaching significance
regarding differences in feeding skills than their matched controls (M = 1.91), t(42) =
2.07, p = .05. Table 5 illustrates a comparison between the two groups of the means and
standard deviations for each of the subscale scores. Table 5 also includes the statistical
results of each analysis.
Table 5
Means and standard deviations for each empirically derived subscale
Subscale
Phenytoin
Control
Food Refusal Items
M 1.45
1.36
SD 1.73
1.81
.18
Stealing/Pica
M .23
SD .53
.39
Feeding Skills
M 2.82
1.91
SD 1.59
1.31
Eats large amount/fast eater
M .32
.73
.94
SD 1.13
Vomit/Rumination
M .55
.23
SD .91
.43
* significance found with alpha set at .02
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Analysis
p = .87
p = .53
p = .05
p = .20
p = .15

Discussion
The present study sought to examine possible feeding problems associated with
the use of three different antiepileptics commonly utilized to control seizures in
individuals with mental retardation. Overall, it appears that seizure medications do not
have a significant effect on the frequency of feeding problems in the MR population as
measured by the STEP. This certainly does not mean that seizure medications do not
have any effect on feeding, rather, it seems that the effects are not enough to cause a
significant difference in frequency of feeding problems when compared to others that are
not on seizure medications. This finding is reassuring given that such a large number of
severely handicapped persons require these drugs. However, it does appear that the one
area that may differ in the MR population with people that are on seizure medications is
in the feeding skills area. As discussed below, there may be a specific deficit (i.e., lack of
motor control) that occurs more often in people with a seizure disorder, and this may
consequently lead to impairment in the area of feeding skills. It is unclear as to whether
these differences are due to the medication side effects, or the inherent differences
between those that need antiepileptic medications and those that do not, but this would
certainly be an informative avenue for future research.
As stated earlier, it was hypothesized that participants on phenytoin would be the
most likely to have significantly more feeding problems than their matched controls.
This hypothesis was based on previous literature that stated that phenytoin has been
associated with more adverse side effects than other seizure medications (Vining, et al.,
1999). Other sources such as The Handbook of Psychiatric Drug Therapy compares
carbamazepine “favorably with the older anticonvulsant, phenytoin”. Later, the
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handbook asserts that valproic acid is “slightly worse than carbamazepine, but superior to
phenytoin…” (1995, p. 124). Despite these findings, the present study found few feeding
problems in any of the antiepileptic groups as compared with their matched control
groups. Only one particular between-group difference was found. Participants on
carbamazepine were significantly more likely to have some sort of feeding skill problem,
as compared to their matched controls. The analysis of between-group differences for the
feeding skills subscale compared the frequencies of the three items that made up the
empirically derived scale. These items were whether the client could feed him/herself
independently, whether the client required special equipment for feeding (i.e., G-tubes,
scoop dishes), and whether the client required special positioning during feeding. An
item analysis revealed that no significant differences between the participants on
carbamazepine and their matched controls were found on each individual item. However,
it was apparent that the item regarding whether the participants needed special equipment
seemed to be nearing significantly greater proportions in the carbamazepine group than
the control group. This suggests that participants that were on the antiepileptic
carbamazepine were more likely to need special equipment when eating than their
matched counterparts.
Although this finding was only significant in the carbamazepine group,
participants in the valproate and phenytoin groups were both very close to significance in
this subscale as well, when compared to their matched controls. Since it seems that all
three of the medication groups were significantly (or close to significantly) more likely to
have a feeding skills problem, it does not seem that it is the property of one certain
antiepileptic medication that is causing these problems. Rather, it could be that a person
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that has a seizure disorder is simply more likely to have a feeding skills problem. For
example, perhaps someone with a seizure disorder has less control over their motor skills
(Kerr, 2002; Mycek, 1997), and therefore needs special equipment in order to eat
properly. The task of sorting out which of these differences was attributable to adverse
medication effects can be difficult given the base rate of physical and behavior problems
often present in this population (Alvarez, et al., 1998). However, because the prevalence
of feeding problems and epilepsy in individuals with mental retardation is growing, these
results may yield some useful information that can aid researchers and clinicians in the
field. Specifically, these results may help researchers to understand that although other
behaviors may be a result of the use of specific antiepileptics, frequency in feeding
problems do not seem to be correlated with these types of seizure medications.
Furthermore, being able to eliminate some possible causes of feeding problems can then
help clinicians in making efficacious treatment decisions (Cooper, et al., 1995).
Although this study was not making comparisons across medication groups, it is
important for researchers and clinicians to be aware of the dosage levels involved with
the medications they are evaluating. The dosage level for each participant was calculated
and categorized into one of 3 groups: high, medium, and low dosage. A low dosage
level was defined as a person receiving 0-50% of a usual daily dose. A medium dosage
level was defined as a person receiving 50-100% of a usual daily dose. Finally, a high
dosage level was defined as a person receiving over 100% of a usual daily dose. The
average daily dosage for participants in the carbamazepine group was in the medium to
high range. The average daily dosage for participants in the valproate and phenytoin
groups were in the low and low to medium range, respectively.
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One issue that was not addressed in this study was the common practice of
polypharmacy. Although all the participants in the experimental groups of this study
were only on one antiepileptic at one time, it is common for patients to be on more than
one antiepileptic simultaneously (Mycek, 1997). Future studies are needed to determine
if the practice of polypharmacy may be of greater consequence in terms of side effects
that may be manifested as feeding problems and other problematic behaviors.
One potentially unavoidable problem was that of the duration of the antiepileptics
used. It was clear that the participants in this study were on these antiepileptics for at
least 5 months, but some were receiving their antiepileptic for a longer amount of time
than others. It was impossible to control for how long each person was on their
medication, if the other variables were to remain the same (such as being on only one
medication). Given this limitation, it is possible that some participants may have not had
enough time to develop side effects, while others may have had enough time. Despite
this, the fact that virtually no significant side effects were noted, lends doubt to whether
this question may have been a serious confound.
Essentially, clinicans and researchers in the field of healthcare must always weigh
the benefits and costs of the treatments they choose for their clients. Given the imminent
dangers that arise if a patient is subjected to seizure activity without treatment, it remains
a fact that some form of proactive treatment is needed for clients with seizure disorders.
Additionally, antiepileptic medications are incredibly effective when used properly.
Although side effects of specific antiepileptics are evident, this study supports that
possible side effects manifested as feeding problems are not frequent enough to warrant
an immediate halt to the use of these antiepileptics in the MR population. However, it
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must be noted that future research must attempt to address some of the issues described in
this study in order to make firmer conclusions on the use of antiepileptic medications.
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